We are happy to announce that patients whose oncologist are satisfied they meet the criteria can now apply for early access to vorasidenib (via their health professional) in the UK under an early access scheme and there is every indication that the drug will be available to those patients very shortly.  

It has been confirmed that the healthcare professional who can instigate an inquiry as to the eligibility of vorsidenib to a particular patient could be their oncologist or neurosurgeon (it is likely that a neuro-consultant could also do this). This is the only method that a patient can access the drug and have eligibility confirmed (reminder – the trial involved LGG patients with IDH mutation who had had surgery but not radiotherapy or chemotherapy and it appears that this criteria is the same for the early access scheme).

Early access is not available in other countries at present – but it will be made available in the future (each country has different processes)

Application to EMA (European Medicines Agency) was made at beginning of January and is being processed. Once EMA approves, this will trigger MHRA (Medicines and Healthcare products Regulatory Agency) application.

Sadly there are a number of patients, having already had further treatment – i.e.radiotherapy and/or chemotherapy, who do not have access to vorasidenib at present – the advice is for patients to regularly contact their health professional as they will have information regarding any upcoming trials.

A BIG THANKS TO ALL THOSE WHO SIGNED AND SHARED THE PETITION AND WROTE TO THEIR MPs 

Astro Brain Tumour Fund are committed to continuing raising funds for research, lobbying for more help for LGG patients and of course to supporting LGG patients, families and carers through our Facebook closed support page.

THANK YOU!!!!!